74 related articles for article (PubMed ID: 22750097)
1. GIV/Girdin transmits signals from multiple receptors by triggering trimeric G protein activation.
Garcia-Marcos M; Ghosh P; Farquhar MG
J Biol Chem; 2015 Mar; 290(11):6697-704. PubMed ID: 25605737
[TBL] [Abstract][Full Text] [Related]
2. Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation.
Waring MJ; Andrews DM; Faulder PF; Flemington V; McKelvie JC; Maman S; Preston M; Raubo P; Robb GR; Roberts K; Rowlinson R; Smith JM; Swarbrick ME; Treinies I; Winter JJ; Wood RJ
Chem Commun (Camb); 2014 May; 50(40):5388-90. PubMed ID: 24366037
[TBL] [Abstract][Full Text] [Related]
3. Cinderella story: PI4P goes from precursor to key signaling molecule.
Tan J; Brill JA
Crit Rev Biochem Mol Biol; 2014; 49(1):33-58. PubMed ID: 24219382
[TBL] [Abstract][Full Text] [Related]
4. Biosynthesis and Significance of Fatty Acids, Glycerophospholipids, and Triacylglycerol in the Processes of Glioblastoma Tumorigenesis.
Korbecki J; Bosiacki M; Gutowska I; Chlubek D; Baranowska-Bosiacka I
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046844
[TBL] [Abstract][Full Text] [Related]
5. High expression of PI4K2A predicted poor prognosis of colon adenocarcinoma (COAD) and correlated with immunity.
Huang X; Cao Y; Bao P; Zhu B; Cheng Z
Cancer Med; 2023 Jan; 12(1):837-851. PubMed ID: 35634680
[TBL] [Abstract][Full Text] [Related]
6. Novel phosphatidylinositol 4-kinases III beta (PI4KIIIβ) inhibitors discovered by virtual screening using free energy models.
Colodette NM; Franco LS; Maia RC; Fokoue HH; Sant'Anna CMR; Barreiro EJ
J Comput Aided Mol Des; 2020 Oct; 34(10):1091-1103. PubMed ID: 32601839
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 4-kinase III beta regulates cell shape, migration, and focal adhesion number.
Bilodeau P; Jacobsen D; Law-Vinh D; Lee JM
Mol Biol Cell; 2020 Aug; 31(17):1904-1916. PubMed ID: 32583740
[TBL] [Abstract][Full Text] [Related]
8. Regulating cellular cyclic adenosine monophosphate: "Sources," "sinks," and now, "tunable valves".
Getz M; Rangamani P; Ghosh P
Wiley Interdiscip Rev Syst Biol Med; 2020 Sep; 12(5):e1490. PubMed ID: 32323924
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells.
Pataer A; Ozpolat B; Shao R; Cashman NR; Plotkin SS; Samuel CE; Lin SH; Kabil NN; Wang J; Majidi M; Fang B; Roth JA; Vaporciyan AA; Wistuba II; Hung MC; Swisher SG
Oncogene; 2020 Jan; 39(4):801-813. PubMed ID: 31554935
[TBL] [Abstract][Full Text] [Related]
10. A predictive computational model reveals that GIV/girdin serves as a tunable valve for EGFR-stimulated cyclic AMP signals.
Getz M; Swanson L; Sahoo D; Ghosh P; Rangamani P
Mol Biol Cell; 2019 Jun; 30(13):1621-1633. PubMed ID: 31017840
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel biomarker in tangeretin‑induced cell death in AGS human gastric cancer cells.
Yumnam S; Raha S; Kim SM; Venkatarame Gowda Saralamma V; Lee HJ; Ha SE; Heo JD; Lee SJ; Kim EH; Lee WS; Kim JA; Kim GS
Oncol Rep; 2018 Dec; 40(6):3249-3260. PubMed ID: 30272339
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PI4K IIIα radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model.
Park Y; Park JM; Kim DH; Kwon J; Kim IA
Oncotarget; 2017 Dec; 8(66):110392-110405. PubMed ID: 29299156
[TBL] [Abstract][Full Text] [Related]
13. Modeling the effects of cyclodextrin on intracellular membrane vesicles from Cos-7 cells prepared by sonication and carbonate treatment.
Kilbride P; Woodward HJ; Tan KB; Thanh NT; Chu KM; Minogue S; Waugh MG
PeerJ; 2015; 3():e1351. PubMed ID: 26528413
[TBL] [Abstract][Full Text] [Related]
14. Amplification of Chromosome 1q Genes Encoding the Phosphoinositide Signalling Enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in Breast Cancer.
Waugh MG
J Cancer; 2014; 5(9):790-6. PubMed ID: 25368680
[TBL] [Abstract][Full Text] [Related]
15. The Concise Guide to PHARMACOLOGY 2013/14: enzymes.
Alexander SP; Benson HE; Faccenda E; Pawson AJ; Sharman JL; Spedding M; Peters JA; Harmar AJ;
Br J Pharmacol; 2013 Dec; 170(8):1797-867. PubMed ID: 24528243
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of phosphatidylinositol 4-kinase type IIIα is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma.
Ilboudo A; Nault JC; Dubois-Pot-Schneider H; Corlu A; Zucman-Rossi J; Samson M; Le Seyec J
BMC Cancer; 2014 Jan; 14():7. PubMed ID: 24393405
[TBL] [Abstract][Full Text] [Related]
17. Mammalian phosphatidylinositol 4-kinases as modulators of membrane trafficking and lipid signaling networks.
Clayton EL; Minogue S; Waugh MG
Prog Lipid Res; 2013 Jul; 52(3):294-304. PubMed ID: 23608234
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer.
Waugh MG
Cancer Lett; 2012 Dec; 325(2):125-31. PubMed ID: 22750097
[TBL] [Abstract][Full Text] [Related]
19. Receptor-mediated signalling pathways acting through hydrolysis of membrane phospholipids in cardiomyocytes.
Lamers JM; De Jonge HW; Panagia V; Van Heugten HA
Cardioscience; 1993 Sep; 4(3):121-31. PubMed ID: 8400019
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
